For the 10th consecutive year, The Blood and Marrow Transplant Program at Northside Hospital Cancer Institute has been recognized as having among the best survival outcomes in the U.S. for bone marrow transplants.
The data was reported by Be The Match, which manages the largest and most diverse marrow registry in the world.
Northside ranks in the top 20% of transplant programs in the country in terms of volume of allogeneic transplants performed. According to the data reported by Be The Match, the one-year survival of patients transplanted at Northside was 79.4%, which exceeds the survival expected for the hospital.
The hospital’s BMT Program is one of only two adult programs, out of 177, in the nation that has achieved survival outcomes that significantly exceed the expected survival rate for the last 10 consecutive reporting cycles and is the longest running adult program in the Southeast to exceed expected survival rates.
H. Kent Holland, M.D., medical director of The BMT Program at Northside Hospital Cancer Institute, believes that these results are a direct reflection of the hard-working dedication of Northside’s physicians and staff.
“We have very experienced team that spearheads the amazing work that takes place in our inpatient and outpatient BMT units, our stem-cell laboratory and blood donor center,” Holland said.
Northside recently began offering chimeric antigen receptor T-cell therapy and other immunotherapy treatment options including novel clinical research trials and is the lead site for a consortium with the Blood and Marrow Transplant Clinical Trials Network, which conducts large multi-institutional clinical trials that address important issues in hematopoietic stem cell transplantation and furthers the understanding of the best possible treatment approaches.